Shire plc and Parion Sciences, Inc., have entered into a collaborative license agreement granting Shire exclusive worldwide rights to develop and commercialize P-321 — an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults -- with the opportunity for Parion to co-fund.
P-321 is a Phase 2 compound reportedly being developed to address tear volume deficiency and promote ocular surface healing. While further clinical trials are reportedly needed to fully evaluate its safety profile and efficacy, P-321 is a novel molecule believed to address dry eye disease by inhibiting ENaC, which is thought to block the absorption of tears, and help keep the ocular surface hydrated.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.